At the same time, manufacturers noted that with two doses, the effectiveness is significantly lower.
The Pfizer/BioNTech vaccine neutralizes the omicron variant at three doses; with two doses the effectiveness is lower. This is stated in a press release that the companies distributed on Wednesday.
“Preliminary data show that the third dose causes a similar level of neutralizing antibodies to the omicron variant, as was seen after two doses against other variants that took place before it,” the companies note.
At the same time, the study showed that with two doses, the effectiveness is significantly lower – “the neutralizing potential is reduced by more than 25 times.” “This indicates that two doses of BNT162b2 do not provide sufficient protection against infection with the omicron strain,” the companies noted.
“Initial data imply that revaccination can provide sufficient protection against disease of any severity caused by the omicron variant,” Ugur Sahin, head of BioNTech, said.